Patents Examined by Robert A. Zeman
  • Patent number: 11104734
    Abstract: Proposed is an anti-PD-1 monoclonal antibody or an antigen binding fragment thereof, comprising a heavy chain variable region having at least one of the amino acid sequences listed below: (1) the amino acid sequence shown in SEQ ID NO: 1; (2) the amino acid sequence shown in SEQ ID NO: 3; (3) the amino acid sequence shown in SEQ ID NO: 5; and (4) an amino acid sequence having more than one conservative amino acid mutation compared with (1)-(3).
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: August 31, 2021
    Assignees: Akeso Biopharma, Inc., Taizhou Hanzhong Biopharmaceutics, Inc.
    Inventors: Yu Xia, Baiyong Li, Zhongmin Maxwell Wang, Faming Zhang, Gan Xi, Ying Huang
  • Patent number: 11097001
    Abstract: A composition/vaccine to intensify and expand the magnitude of the host immune response against the Ag 85 and ESAT6 proteins thereby blocking the inhibitory effect of these two classes of secreted proteins, and thus promoting the clearing or control of the MTb infection. Fusion proteins are created between immunogenic fragments of the soluble secreted MTb proteins Ag 85 and ESAT6 (which are inhibitors of the immune response) and the extracellular domain (ecd) of the immunostimulatory protein ecdCD40 ligand (ecdCD40L). Fusion proteins are created using both Ag85 and ESAT-6 immunogenic peptides and ecdCD40L, to induce a more potent immune response against the MTb than would the use of either protein (Ag85 or ESAT-6) alone. Both a humoral and cellular immune response are induced. The composition/vaccine further avoids the requirement for use of attenuated strains of the tubercle bacillis, to induce an immune response to the Ag85 and ESAT6 proteins.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: August 24, 2021
    Assignee: MicroVAX, LLC
    Inventor: Albert B. Deisseroth
  • Patent number: 11099188
    Abstract: The invention provides the identification of the presence of polypeptides with ROS kinase activity in mammalian lung cancer. In some embodiments, the polypeptide with ROS kinase activity is the result of a fusion between a ROS-encoding polynucleotide and a polynucleotide encoding a second (non-ROS) polypeptide. Three different fusion partners of ROS are described, namely proteins encoded by the FIG gene, the SLC34A2 gene, and the CD74 gene. The invention enables new methods for determining the presence of a polypeptide with ROS kinase activity in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer (e.g., an lung cancer).
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 24, 2021
    Inventors: Victoria McGuinness Rimkunas, Herbert Haack, Ting-Lei Gu, Ailan Guo, Anthony Paul Possemato, Katherine Eleanor Crosby, Meghan Ann Tucker, Cynthia Beaudet
  • Patent number: 11090341
    Abstract: Provided herein are methods and compositions related to Veillonella bacteria useful as therapeutic agents.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: August 17, 2021
    Assignee: Evelo Biosciences, Inc.
    Inventors: Brian Goodman, Baundauna Bose, Christopher J. H. Davitt, Maria Sizova, Sofia M. R. Carlton, Andrea Itano, Holly Ponichtera, Taylor A. Cormack, Kritika Ramani
  • Patent number: 11091521
    Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: August 17, 2021
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Rhea N. Coler, Gregory C. Ireton, Sylvie Bertholet
  • Patent number: 11066652
    Abstract: The invention provides peptides derived from a ubiquitous protein, and nucleic acids encoding such peptides. The invention extends to various uses of these peptides and nucleic acids, for example, as antigens for use in vaccines per se and in the generation of antibodies for use in therapeutic drugs for the prevention, amelioration or treatment of infections caused by sepsis-inducing bacteria. The invention particularly benefits immunocompromised hosts such as neonates, babies, children, women of fertile age, pregnant women, foetuses, the elderly and diabetics.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: July 20, 2021
    Assignee: Universidade do Porto—Reitoria
    Inventors: Paula Maria Das Neves Ferreira Da Silva, Pedro Jorge Fonseca Madureira
  • Patent number: 11066450
    Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHbp which can be modified to enhance their properties.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: July 20, 2021
    Inventors: Matthew Bottomley, Vega Masignani
  • Patent number: 11034965
    Abstract: Described herein are bacterial microcompartments shell proteins modified to stably incorporate iron-sulfur clusters. Such bacterial microcompartments shell proteins exhibit redox cycling and confer electron transfer functionality to bacterial microcompartment shells.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: June 15, 2021
    Assignee: Board of Trustees of Michigan State University
    Inventors: Cheryl A. Kerfeld, Clement Aussignargues
  • Patent number: 11035856
    Abstract: Method and compositions using transition metal salts and/or ammonium chloride to liberate toxins and other molecules from cyanobacteria, useful for assaying for total cyanobacterial toxins in lakes, reservoirs and other waters.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: June 15, 2021
    Assignee: Abraxis, Inc.
    Inventors: Fernando Manuel Rubio, Lisa Marie Kamp
  • Patent number: 11034735
    Abstract: The present invention relates to novel hybrid peptides developed from the combination of membrane surface protein peptide fragments present in anaplasmosis microorganisms, and in particular, bacteria of the species Anaplasma marginale. The present invention further relates to hybrid peptide sets, compositions and kits comprising such novel hybrid peptides, their uses and methods of inducing immune response. Each hybrid peptide, according to the present invention, comprises two or more peptide fragments of amino acid sequences as defined in the present invention linked together by means of a spacer element. The combined peptide fragments are protein peptide fragments of MSP1, MSP1a, MSP1b, MSP2, MSP2-HRV, MSP3, OMP7, OMP8, VirB9 and VirB10.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: June 15, 2021
    Inventors: Ana Marisa Chudzinski-Tavassi, Bárbara Athayde Vaz Galväo da Silva, Kerly Fernanda Mesquita Pasqualoto, Leo Kei Iwai, Rafael Marques Porto
  • Patent number: 11021534
    Abstract: The present invention provides an antigenic composition for use as a mycobacterial vaccine, said composition comprising (i) a first mycobacterial antigenic polypeptide, wherein said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 6, 12, 2, 18, 8, 10, 16, 4, or a fragment thereof having at least 50 consecutive amino acids thereof; or (ii) a first mycobacterial polynucleotide, wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide, or wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence selected from SEQ ID NO: 5, 11, 1, 17, 7, 9, 15, 3.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: June 1, 2021
    Inventors: Yper Hall, Joanna Bacon, Philip Marsh
  • Patent number: 11020468
    Abstract: The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with Propionibacterium acnes. The compositions include a combination of peptide and anti-TNF. The peptide consists of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived the specific amino acid sequence by deletion, substitution, insertion or addition of one or more amino acids. The administration of the peptide and anti-TNF in therapeutically effective amounts to a patient is effective to suppress, by immune response, inflammation caused by infection with Propionibacterium acnes.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: June 1, 2021
    Inventor: Kenichiro Hasumi
  • Patent number: 11021535
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: June 1, 2021
    Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Sanaria Inc.
    Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
  • Patent number: 11013799
    Abstract: The present invention provides compositions and methods for enhancing immunogenicity of polysaccharide antigens. Immunogenic compositions and vaccines comprising polysaccharide-protein conjugates comprising a chimeric carrier protein having a universal epitope are provided. Methods of preparing the compositions, and methods for treating or preventing bacterial infections are further provided. The compositions and methods are useful for enhancing immune response in young children, elderly and immunocompromised individuals.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: May 25, 2021
    Inventor: Jianping Li
  • Patent number: 11000579
    Abstract: Provided herein are immunogenic compositions containing recombinant proteins capable of presenting all, or antigenic portions of, the Eimeria maxima, Eimeria tenella, and Eimeria acervulina IMP1 protein in developing active immunity to, and control of, coccidiosis. Also provided are methodologies of using the immunogenic compositions for administration to poultry and other animals in the control of coccidiosis. Nanoparticle-conjugated rIMP1 immunogenic compositions and methods of making and using them are provided.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: May 11, 2021
    Assignees: The United States of America, as represented by The Secretary of Agriculture, Board of Trustees of Souther Illinois University
    Inventors: Mark C. Jenkins, Vjollca Konjufca
  • Patent number: 10973897
    Abstract: The present specification discloses Trypanosoma antigens, immunogenic compositions and medicaments comprising such Trypanosoma antigens, methods and uses for such Trypanosoma antigens and immunogenic compositions for treating a Trypanosoma-based disease.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: April 13, 2021
    Assignee: PepTcell Limited
    Inventors: Olga Pleguezuelos Mateo, Wilson Caparros-Wanderley, Gregory A. Stoloff
  • Patent number: 10968258
    Abstract: The present invention provides S. suis strains that elicit an immune response in animal S. suis, compositions comprising said strains, methods of vaccination against S. suis, and kits for use with such methods and compositions. The invention further provides a comprehensive, unambiguous method of capsular typing based on whole genome sequencing and bioinformatics. This capsular typing approach can accurately identify serotypes even when strains possess novel capsular loci and can be used to determine which strains to include when formulating vaccines, including herd specific vaccines.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 6, 2021
    Inventor: Paulraj Lawrence
  • Patent number: 10960068
    Abstract: Vaccine vectors and methods for enhancing resistance to Campylobacter infection or for enhancing the immune response to Campylobacter are provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO: 7-9 or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: March 30, 2021
    Inventors: Billy Hargis, Neil R. Pumford, Young Min Kwon, Sherryll Layton
  • Patent number: 10961298
    Abstract: Described are a therapeutic monoclonal antibody specific for the Type Six Secretion System (T6SS) needle protein of Acinetobacter baumannii (A. baumannii) and methods of use. Specifically, the antibody specifically binds to hemolysin co-regulated protein (Hep). Further disclosed are methods of using an anti-Hep antibody for detecting A. baumannii in a sample as well as a mutant A. baumannii strain comprising a deletion or mutation in its genome such that said deletion or mutation interrupts the proper translation of its hep protein.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: March 30, 2021
    Assignee: The Government of The United States, Represented by the Secretary of the Army
    Inventor: Daniel V. Zurawski
  • Patent number: 10960066
    Abstract: Provided is a method of treating or preventing pneumococcal disease. Also provided is a method of diagnosing pneumococcal disease.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: March 30, 2021
    Inventors: Jing-Ren Zhang, Yang Wang, Zhensong Wen